Topics include intermediate-risk bladder cancer, BCG-unresponsive disease ... a novel ureteroscopic technology combining microjet irrigation and dynamic aspiration. He demonstrates improved stone ...

Aidixi plus BCG showed strong early efficacy and manageable safety in patients with high-risk, HER2-expressing ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

LAS VEGAS -- Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC).

Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for ...

in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus Calmette-Guérin (BCG), a randomized ...

in patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). The system was particularly effective in patients with carcinoma in situ (CIS), ...

Up to 50% of patients with high-risk non-muscle invasive bladder cancer may experience failure of BCG intravesical immunotherapy, yet it has been the standard of care after tumor resection for decades ...